---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-393081"
form_type: "8-K"
ticker: "AVLN"
cik: "0001540171"
company_name: "Avalyn Pharma Inc."
filed_at: "2026-09-16T20:13:18+00:00"
generated_at: "2026-09-16T20:15:16.602487+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Avalyn Pharma appoints former FDA director Robert Meyer to board

## Summary
- Appointed Robert Meyer, M.D. as Class II director effective Sept 15, 2026; term expires at 2028 annual meeting.
- Meyer is independent under Nasdaq rules; ex-FDA drug evaluation director and Merck VP for global regulatory strategy.
- Eligible for $40,000 annual retainer; initial option for 31,182 shares vesting over 3 years plus annual 15,591-share grants.
- No arrangements or transactions requiring disclosure; signed standard indemnification agreement.

## SEC filing metadata
- accession: 0001193125-26-393081
- form_type: 8-K
- ticker: AVLN
- cik: 0001540171
- company_name: Avalyn Pharma Inc.
- filed_at: 2026-09-16T20:13:18+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1540171/000119312526393081/0001193125-26-393081-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1540171/000119312526393081/ck0001540171-20260915.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-393081
- JSON: https://secwatch.observer/filing/0001193125-26-393081.json
- Plain text: https://secwatch.observer/filing/0001193125-26-393081.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.